Cited by 1,162Pulmonary Hypertension Research and TreatmentsPharmacology and Obesity TreatmentPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension

Open access

Abenhaim, Lucien, Moride, Yola, Brenot, François, Rich, Stuart, Benichou, Jacques, Kurz, Xavier, Higenbottam, Tim, Oakley, Celia, Wouters, Emil, Aubier, Michel, Simonneau, Gérald, Bégaud, Bernard·1996·New England Journal of Medicine

DOI 10.1056/nejm199608293350901

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Recently, a cluster of patients was observed in France in whom primary pulmonary hypertension developed in patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. METHODS: In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age. RESULTS: The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used to a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs. CONCLUSIONS: The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since their use is expected to increase in the near future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199608293350901

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Primary Pulmonary Hypertension
Rich, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., Detre, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,027
Self-citation
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,558
Self-citation
Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 701
Increased plasma serotonin in primary pulmonary hypertension
Hervé, P., Launay, J., Scrobohaci, M.-L., Brenot, F., Simonneau, G., PETITPRETZ, P., Poubeau, P., Cerrina, J., Duroux, P., & Drouet, L. O. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80156-9 · Cited by 557
Self-citation
Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics
Hadengue, A., Benhayoun, M. K., Lebrec, D., & Benhamou, J. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90225-a · Cited by 497
Primary Pulmonary Hypertension and Cirrhosis: Are They Related?
McDonnell, P. J., Toye, P. A., & Hutchins, G. M. (1983) · American Review of Respiratory Disease · doi:10.1164/arrd.1983.127.4.437 · Cited by 318
Primary Pulmonary Hypertension
Rubin, L. J. (1993) · CHEST Journal · doi:10.1378/chest.104.1.236 · Cited by 308
Primary pulmonary hypertension and fenfluramine use.
Brénot, F., Hervé, P., PETITPRETZ, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 247
Self-citation
Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension.
PETITPRETZ, P., Brénot, F., Azarian, R., Parent, F., Rain, B., Hervé, P., & Simonneau, G. (1994) · Circulation · doi:10.1161/01.cir.89.6.2722 · Cited by 238
Self-citation
Pulmonary hypertension and fenfluramine
Douglas, J. G., Munro, J., KITCHIN, A. H., Muir, A. L., & Proudfoot, A. T. (1981) · BMJ · doi:10.1136/bmj.283.6296.881 · Cited by 180

Show all 26 references

Research works printed but not linked: 3

Gurtner HP, 1985, Cor Vasa, 27, 160
Michelakis ED, 1995, Am J Respir Crit Care Med, 151, A725
Russel LA, 1992, Am Rev Respir Dis, 145, A717

Sorted by citations

Items 601–700 of 999

Emerging Molecular Targets for Anti-proliferative Strategies in Pulmonary Arterial Hypertension
Tu, L., & Guignabert, C. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-38664-0_17 · Cited by 19
PHARMACOVIGILANCE IN INDIA: PERSPECTIVES AND PROSPECTS
Kumar, S., & Baldi, A. (2013) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v3i4.619 · Cited by 15
Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: A multicentre study
Maréchaux, S., Jeu, A., Jobic, Y., Éderhy, S., Donal, E., Réant, P., Abouth, S., Arnasteen, E., Boulanger, J., Ennezat, P., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.006 · Cited by 15
Primary haemochromatosis: a missed cause of chronic fatigue syndrome?
Swinkels, D. W., Aalbers, N., Elving, L. D., Bleijenberg, G., Swanink, C. M. A., & van der Meer, J. W. M. (2002) · PubMed · Cited by 15
The Acute Effects of Dexfenfluramine on Human and Porcine Pulmonary Vascular Tone and Resistance
HIGENBOTTAM, T. W., Marriott, H. M., Cremona, G., Laude, E. A., & Bee, D. (1999) · CHEST Journal · doi:10.1378/chest.116.4.921 · Cited by 15
Self-citation
Genetics of Pulmonary Arterial Hypertension
Elliott, C. G. (2013) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.08.003 · Cited by 15
Saudi guidelines on diagnosis and treatment of pulmonary arterial hypertension
Majdy, I., Al-Hajjaj, M. S., Javeed, K., Manal, A.-H., Alanezi, M. O., Saleemi, S., Sanai, F. M., Kashour, T. S., Wali, S., & Barst, R. J. (2008) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 14
Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding
Dini, G., Cara, G. D., Ferrara, P., Striano, P., & Verrottı, A. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s417676 · Cited by 14
New approaches to strengthen pharmacovigilance
Arlett, P. R., & Kurz, X. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.03.003 · Cited by 16
Self-citation
Classification of Pulmonary Hypertension
McGlothlin, D. P. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.04.013 · Cited by 14
Genomics of Pulmonary Arterial Hypertension: Implications for Therapy
Geraci, M. W., Bull, T. M., & Tuder, R. M. (2009) · Heart Failure Clinics · doi:10.1016/j.hfc.2009.08.001 · Cited by 15
Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Management of Patients With Valvular Heart Disease: A Report of the American College 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the
Shah, P. M., Shanewise, J. S., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., O’Rourke, R. A., Otto, C. M., Faxon, D. P., Freed, M. D., Gaasch, W. H., et al. (2013) · Cited by 14
New Antiobesity Agents
Shyh, G. I., & Cheng-Lai, A. (2013) · Cardiology in Review · doi:10.1097/crd.0000000000000001 · Cited by 15
Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead
Pérez, V. D. J., Kudelko, K. T., Snook, S., & Zamanian, R. T. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02606.x · Cited by 14
Models for pulmonary hypertension
Marsboom, G., & Janssens, S. P. (2004) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2004.11.026 · Cited by 14
Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents
Walter, C. P., Bleske, B. E., & Dorsch, M. P. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12177 · Cited by 14
Role of the serotonin transporter in pulmonary arterial hypertension
Dempsie, Y., & MacLean, M. R. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.6.749 · Cited by 14
Estudio clínico-hemodinámico y tratamiento de 44 pacientes con hipertensión pulmonar primaria
Román, A., Lara, B., Bravo, C., Monforte, V., Morell, F., Rodés‐Cabau, J., Pallisa, E., & Domingo, E. (2002) · Medicina Clínica · doi:10.1016/s0025-7753(02)72524-4 · Cited by 14
The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux
Johnson, G. J., Leis, L. A., Dunlop, P. C., & Weir, Ε. K. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00474.x · Cited by 14
EPIDEMIOLOGY OF ADVANCED LUNG DISEASE IN THE UNITED STATES
Bresnitz, E. A. (1997) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70392-0 · Cited by 14
Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension
Rochefort, G. Y., Lemaire, M.-C., Eder, V., Hanton, G. C., Hyvelin, J.-M., Bonnet, P., & Antier, D. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.08.050 · Cited by 14
Gene expression in lungs of mice lacking the 5-hydroxytryptamine transporter gene
Crona, D. J., Harral, J. W., Adnot, S., Eddahibi, S., & West, J. D. (2009) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-9-19 · Cited by 14
Anorectic drugs and vascular disease:
Michelakis, E. D. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00126-x · Cited by 14
The Pulmonary Hypertensive Fawn-hooded Rat Has a Normal Serotonin Transporter Coding Sequence
González, A.-M., Smith, A. P. L., Emery, C., & HIGENBOTTAM, T. W. (1998) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.19.2.3073 · Cited by 14
Self-citation
Medical management of obstructive sleep apnea
Henderson, J. H., & Strollo, P. J. (1999) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.1999.0410377 · Cited by 14
From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications
Bialer, M., & Perucca, E. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108808 · Cited by 13
Pulmonary Arterial Hypertension: Emerging Principles of Precision Medicine across Basic Science to Clinical Practice
Kelly, N. J., & Chan, S. Y. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311378 · Cited by 14
Efficacy of pharmacological treatments for Dravet syndrome: Systematic review and network meta-analysis
Xia, D., Zhang, P., Chen, Y., Liu, X., & Chen, Y. (2024) · Seizure · doi:10.1016/j.seizure.2024.02.004 · Cited by 15
Pulmonary Arterial Hypertension Secondary to Drugs and Toxins
Ramírez, R. L., Pienkos, S. M., Pérez, V. D. J., & Zamanian, R. T. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.11.008 · Cited by 13
Novel and emerging therapies in pulmonary arterial hypertension
Cassady, S. J., Soldin, D., & Ramani, G. V. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1022971 · Cited by 14
Novel investigational therapies for treating pulmonary arterial hypertension
Sardana, M., Moll, M. R., & Farber, H. W. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1098616 · Cited by 13
Combination of very low energy diets and pharmacotherapy in the treatment of obesity: meta‐analysis of published data
Koutroumanidou, E., & Pagonopoulou, O. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2475 · Cited by 13
Polimorfismos en el gen de la proteína transportadora de serotonina (SERT) en pacientes con hipertensión arterial pulmonar
Baloira, A., Fernández, M. N., Martínez, J. M. C., Vilariño, C., Ojeda, M., & Valverde, D. (2011) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2011.10.008 · Cited by 13
Treating obesity. Lost cause or new opportunity?
Plourde, G. (2000) · PubMed Central · Cited by 13
Evaluation of the Serotonin Receptor Blocker Methiothepin in Broilers Injected Intravenously with Lipopolysaccharide and Microparticles
Chapman, M. E., & Wideman, R. F. (2006) · Poultry Science · doi:10.1093/ps/85.12.2222 · Cited by 13
Selective Serotonin Reuptake Inhibitor Use Is Associated with Right Ventricular Structure and Function: The MESA-Right Ventricle Study
Ventetuolo, C. E., Barr, R. G., Bluemke, D. A., Jain, A., Delaney, J. A., Hundley, W. G., Lima, J. A. C., & Kawut, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030480 · Cited by 12
Appetite Suppressant Drugs as Inhibitors of Human Cytochromes P450
Moltke, L. L., Greenblatt, D. J., Ciraulo, D. A., Grassi, J. M., Granda, B. W., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00015 · Cited by 13
Current Management of Primary Pulmonary Hypertension
Backer, T. L. M. D., Smedema, J., & Carlier, S. P. G. (2001) · BioDrugs · doi:10.2165/00063030-200115120-00003 · Cited by 13
Elevated gastrin secretion by in vivo gene electroporation in skeletal muscle
Yasui, A., Oda, K., Usunomiya, H., Kakudo, K., Suzuki, T., Yoshida, T., Park, H.-M., Fukazawa, K., & Muramatsu, T. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.8.5.489 · Cited by 13
Pulmonary Hypertension: New Perspectives
Nauser, T. D., & Stites, S. W. (2003) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2002.01050.x · Cited by 13
The tantalizing triplet of pulmonary hypertension—BMP receptors, serotonin receptors, and angiopoietins
Eickelberg, O. (2003) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.10.017 · Cited by 13
Benfluorex (Mediator®) et atteintes valvulaires
Tribouilloy, C. M., Jeu, A., Maréchaux, S., Jobic, Y., Ruşinaru, D., & Andréjak, M. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.09.001 · Cited by 12
Traditional medicine Taeeumjowitangkagambang exerts antiobesity and hypolipidemic effects via antioxidant enzyme enhancement
Park, C., Jeong, S., Lee, H., Lee, E., Bae, H., Lee, M., Kim, S., Jung, H., Ahn, K. S., & Kim, S. (2010) · Phytotherapy Research · doi:10.1002/ptr.3179 · Cited by 12
Can we win the war on obesity with pharmacotherapy?
Gotthardt, J. D., & Bello, N. T. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1232164 · Cited by 11
Current and emerging pharmacotherapies for obesity in Australia
HOCKING, S. L., Dear, A. E., & Cowley, M. A. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2017.07.002 · Cited by 12
Development of a Peripherally Restricted 5-HT2B Partial Agonist for Treatment of Pulmonary Arterial Hypertension
Valentine, M. S., Bender, A. M., Shay, S. D., Paffenroth, K. C., Gladson, S., Dickerson, J. W., Watson, K. J., Kapolka, N. J., Boutaud, O. G., Rook, J. M., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.06.014 · Cited by 12
Transforming growth factor signalling: a common pathway in pulmonary arterial hypertension and systemic sclerosis
Hatton, N. D., Frech, T., Smith, B., Sawitzke, A. D., Scholand, M. B., & Markewitz, B. A. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02726.x · Cited by 12
Pulmonary Arterial Hypertension: Evaluation and Management
LaRaia, A. V., & Waxman, A. B. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e31802f2ff1 · Cited by 12
Methods in pharmacoepidemiology
Sommet, A., & Pariente, A. (2019) · Therapies · doi:10.1016/j.therap.2018.11.015 · Cited by 16
The Kv2.2 alpha subunit contributes to delayed rectifier K(+) currents in myocytes from rabbit corpus cavernosum.
Malysz, J., Farrugia, G., Ou, Y., Szurszewski, J. H., Nehra, A. X., & Gibbons, S. J. (2002) · PubMed · Cited by 12
Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status
Whigham, L. D., Dhurandhar, N. V., Rahko, P. S., & Atkinson, R. L. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803498 · Cited by 12
Effective management of obesity.
O’Meara, S., Glenny, A., Wilson, C., Melville, A., & Sheldon, T. (1997) · BMJ Quality & Safety · doi:10.1136/qshc.6.3.170 · Cited by 12
Bone morphogenetic protein receptor-II mutation Arg491Trp causes malignant phenotype of familial primary pulmonary hypertension
Zhicheng, J., Lu, L., Zhiyan, H., Xiansheng, C., Yubao, Z., Yuejin, Y., & Hui, R. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.158 · Cited by 12
Interim report on the incidence of visual field defects in patients on long term vigabatrin therapy
Wilton, L., Stephens, M. D. B., & Mann, R. D. (1999) · Pharmacoepidemiology and Drug Safety · doi:10.1002/(sici)1099-1557(199904)8:1+ · Cited by 17
Self-citation
Estrogen Oppositely Regulates Pulmonary Hypertension via METTL3/PFKFB3 under Normoxia and Hypoxia
Li, X., Wang, J., Chen, Y., Li, P., Wen, H. Y., Xu, X., Wang, J., Xu, Y., Chen, Y., Song, J., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0042oc · Cited by 11
Guidelines for the initiation of obesity treatment
Atkinson, R. L. (1998) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(98)00033-3 · Cited by 11
Survival and Prognostic Factors in Patients with Primary Pulmonary Hypertension
Chun, K., Kim, S. H., An, B. J., Kim, S. H., Ha, J. K., Hong, T. J., & Shin, Y. W. (2001) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2001.16.2.75 · Cited by 11
Specific N-terminal CGRP fragments mitigate chronic hypoxic pulmonary hypertension in rats
Qing, X., Wimalawansa, S. J., & Keith, I. M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00211-2 · Cited by 11
Death from irreversible pulmonary hypertension associated with short-term use of fenfluramine and phentermine.
Dillon, K. A., Putnam, K. G., & Avorn, J. (1997) · PubMed · Cited by 11
Pulmonary hypertension as a result of drug therapy
Higenbottam, T., Laude, L., Emery, C., & Essener, M. (2004) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00133-3 · Cited by 11
Self-citation
Diagnosis and evaluation of the patient with pulmonary hypertension
Kim, N. H. S. (2004) · Cardiology Clinics · doi:10.1016/j.ccl.2004.04.003 · Cited by 11
Toxicidad pulmonar por fármacos
Valero, F. C., & Pardo, J. M. (1999) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(15)30008-9 · Cited by 11
The treatment of obesity. A call for prudence and professionalism.
Kushner, R. F. (1997) · PubMed · Cited by 11
Serotonin in Pulmonary Arterial Hypertension
Naeije, R., & Eddahibi, S. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2406002 · Cited by 11
Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes
Muhle, H., Kurlemann, G., Lehmann, I., Hamer, H. M., Mayer, T., Potschka, H., Schubert‐Bast, S., Strzelczyk, A., & Pringsheim, M. (2024) · Clinical Epileptology · doi:10.1007/s10309-023-00646-5 · Cited by 10
Innovative LC-MS/MS method for therapeutic drug monitoring of fenfluramine and cannabidiol in the plasma of pediatric patients with epilepsy
Pigliasco, F., Cafaro, A., Barco, S., Stella, M., Mattioli, F., Riva, A., Mancardi, M. M., Lattanzi, S., Bandettini, R., Striano, P., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116174 · Cited by 10
Indigo Naturalis in Inflammatory Bowel Disease: mechanisms of action and insights from clinical trials
Kim, H., Jeong, S., Kim, S. W., Kim, H.-J., Kim, D. Y., Yook, T. H., & Yang, G. (2024) · Journal of pharmacopuncture · doi:10.3831/kpi.2024.27.2.59 · Cited by 10
Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines
Green, M. P., McMurray, G., & Storer, R. I. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.06.060 · Cited by 10
Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta‐analysis
Zhang, L., Li, W., & Wang, C. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13387 · Cited by 10
Prevention of coronary heart disease
Liebson, P. R., & Amsterdam, E. A. (2000) · Disease-a-Month · doi:10.1016/s0011-5029(00)90016-6 · Cited by 10
Dexfenfluramine discontinuous treatment does not worsen hypoxia-induced pulmonary vascular remodeling but activates RhoA/ROCK pathway: Consequences on pulmonary hypertension
Desbuards, N., Antier, D., Rochefort, G. Y., Apfeldorfer, C. S., Schenck, E., Hanton, G. C., & Hyvelin, J.-M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.11.025 · Cited by 10
Adverse Drug Reactions in the Intensive Care Unit
Moore, P. W., & Burkhart, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-17900-1_33 · Cited by 10
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications
Elliott, C. G., Austin, E. D., Badesch, D. B., Badlam, J. B., Benza, R. L., Chung, W. K., Farber, H. W., Feldkircher, K., Frost, A., Poms, A. D., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019851696 · Cited by 10
Mechanisms responsible for pulmonary hypertension.
Mainali, P., Jin, H., Tian, Y., Tang, C., & Du, J. (2008) · PubMed · Cited by 10
High performance liquid chromatographic determination of mazindol in human plasma.
Kaddoumi, A., Mori, M., Nanashima, K., Kono, M., & Nakashima, K. (2001) · The Analyst · doi:10.1039/b106008m · Cited by 10
Recent trends in pulmonary arterial hypertension
Natarajan, R. (2011) · Lung India · doi:10.4103/0970-2113.76300 · Cited by 10
Epoprostenol in pulmonary arterial hypertension
Jacobs, W., & Noordegraaf, A. V. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802622962 · Cited by 10
Hypertension artérielle pulmonaire isolée et pergolide
Evrard, F., Dupuis, M., Müller, T., & Jacquerye, P. (2008) · Revue Neurologique · doi:10.1016/j.neurol.2007.09.005 · Cited by 10
Fenfluramine: riddle or Rosetta stone?
Weir, Ε. K., Obreztchikova, M. N., & Hong, Z. (2008) · European Respiratory Journal · doi:10.1183/09031936.00160407 · Cited by 10
Adverse Effects of Observational Studies When Examining Adverse Outcomes of Drugs
Austin, P. C., Mamdani, M., & Williams, I. J. (2002) · Drug Safety · doi:10.2165/00002018-200225090-00006 · Cited by 10
Traitement de l'hypertension artérielle pulmonaire de l'enfant
Fraisse, A., & Habib, G. (2004) · Archives de Pédiatrie · doi:10.1016/j.arcped.2004.01.026 · Cited by 10
PHARMACEUTICAL TREATMENT OF OBESITY
Blackburn, G. L., Miller, D. L., & Chan, S. (1997) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)02695-0 · Cited by 10
Digital Necrosis Associated with Dexfenfluramine
Marinella, M. A., & Berrettoni, B. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372415 · Cited by 10
The Age-Adjusted Mortality Rate From Primary Pulmonary Hypertension, in Age Range 20 to 54 Years, Did Not Increase During the Years of Peak “Phen/Fen” Use
Rothman, R. B. (2000) · CHEST Journal · doi:10.1378/chest.118.5.1516 · Cited by 10
A Review of Serotonin in the Developing Lung and Neonatal Pulmonary Hypertension
Archambault, J. L., & Delaney, C. A. (2023) · Biomedicines · doi:10.3390/biomedicines11113049 · Cited by 9
Metabolomic Evidence of Biological Overlap with Heart Failure with Preserved Ejection Fraction in a Subset of Pulmonary Arterial Hypertension
Reddy, Y. N. V., Asokan, A. K., Frantz, R. P., Hemnes, A. R., Hassoun, P. M., Barnard, J., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202501-0034oc · Cited by 10
Guidelines for the assessment and management of residual sleepiness in obstructive apnea-hypopnea syndrome
Barateau, L., Baillieul, S., Andréjak, C., Béquignon, É., Boutouyrie, P., Dauvilliers, Y. A., Gagnadoux, F., Geoffroy, P. A., Micoulaud‐Franchi, J., Montani, D., et al. (2024) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2024.101105 · Cited by 10
Sérotonine et hypertension artérielle pulmonaire
Eddahibi, S., & Adnot, S. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)71561-3 · Cited by 9
Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti‐obesity drugs
Willemen, M. J. C., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Leufkens, H. G. M., Egberts, T. C. G., & Sturkenboom, M. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1759 · Cited by 9
Development of an analytical method for simultaneous detection of psychotropic phenylalkylamines in hair by LC-MS/MS with a multi-mode reversed-phase column using pH gradient elution
Choi, H., Kim, S., Ahn, S. Y., Chang, H., Lee, S., & Lee, Y. (2015) · Forensic Science International · doi:10.1016/j.forsciint.2015.12.016 · Cited by 9
Pulmonary Hypertension Detection Using Dynamic and Static Measurable Parameters on CT Angiography
Siegel, Y., & Mirpuri, T. M. (2014) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000091 · Cited by 9
Simultaneous Determination of Fenfluramine and Phentermine in Urine Using Gas Chromatography Mass Spectrometry With Pentafluoropropionic Anhydride Derivatization
Palmer, R. B., Kim, N.-H., & Dasgupta, A. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200008000-00009 · Cited by 9
Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension
Chaumais, M., O’Connell, C., Savale, L., Guignabert, C., Perros, F., Jaïs, X., Sitbon, O., Humbert, M. J. C., & Montani, D. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0712-y · Cited by 9
Polymorphisms in the Serotonin Transporter Protein (SERT) Gene in Patients With Pulmonary Arterial Hypertension
Baloira, A., Fernández, M. N., Martínez, J. M. C., Vilariño, C., Ojeda, M., & Valverde, D. (2012) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2011.10.006 · Cited by 9
Pharmacotherapy for weight management.
Palatty, P. L., & Saldanha, E. (2012) · PubMed · Cited by 9
Epidemiology and ‘big data’
Stricker, B. H. C. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0294-3 · Cited by 9
Obesity, metabolic syndrome, and disorders of energy balance
Weiss, R., & Lustig, R. H. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00031-7 · Cited by 9
Mechanisms responsible for pulmonary hypertension
Mainali, P., Jin, H., Tian, Y., Tang, C., & Du, J. (2008) · Chinese Medical Journal · doi:10.1097/00029330-200812020-00024 · Cited by 9
Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era
Jacobs, W., Boonstra, A., Brand, M., Rosenberg, D., Schaaf, B., Postmus, P. E., & Noordegraaf, A. V. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.011 · Cited by 9
(+)-Norfenfluramine-Induced Arterial Contraction Is Not Dependent on Endogenous 5-Hydroxytryptamine or 5-Hydroxytryptamine Transporter
Ni, W., Wilhelm, C. S., Bäder, M., Murphy, D. L., Lookingland, K. J., & Watts, S. W. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087080 · Cited by 9

Authors: Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., & Bégaud, B.
Affiliations: Jewish General Hospital (CA)
Hôpital Antoine-Béclère (FR)
University of Illinois Chicago (US)
Centre Hospitalier Universitaire de Liège (BE)
University of Sheffield (GB)
Hammersmith Hospital (GB)
Maastricht University Medical Centre (NL)
Hôpital Bichat-Claude-Bernard (FR)
Hôpital Pellegrin (FR)
ORCID: Abenhaim, Lucien
Moride, Yola
Rich, Stuart
Kurz, Xavier
Higenbottam, Tim
Simonneau, Gérald
Bégaud, Bernard
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1996-08-29
Volume: 335
Issue: 9
Pages: 609-616
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199608293350901
OpenAlex: W2329065056
Cited by: 1,162
References: 26
Citations by year: 2026: 7 · 2025: 23 · 2024: 22 · 2023: 21 · 2022: 22 · 2021: 16 · 2020: 16 · 2019: 20 · 2018: 27 · 2017: 29 · 2016: 18 · 2015: 30 · 2014: 27 · 2013: 39 · 2012: 34
FWCI: 71.92
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research Publications (Maastricht University) (publishedVersion)
Research Publications (Maastricht University) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: idiopathic pulmonary arterial hypertension, appetite suppressants, drug-induced pulmonary hypertension, risk factors, HIV infection, liver cirrhosis, cocaine use, intravenous drug use, weight management
MeSH terms: Adolescent, Adult, Aged, Appetite Depressants, Belgium, Female, Fenfluramine, France, United Kingdom, Heart Function Tests, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Netherlands, Prospective Studies, Respiratory Function Tests, Risk Factors, Incidence, Logistic Models, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks